Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04AEQ
|
|||
| Former ID |
DIB002281
|
|||
| Drug Name |
V81444
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 1/2 | [1] | |
| Advanced cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [2] | ||
| Company |
Vernalis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H21N7O3
|
|||
| Canonical SMILES |
CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5
|
|||
| InChI |
1S/C20H21N7O3/c1-12-5-6-16(30-12)17-18-19(24-20(21)23-17)27(26-25-18)9-13-3-2-4-14(22-13)10-29-15-7-8-28-11-15/h2-6,15H,7-11H2,1H3,(H2,21,23,24)/t15-/m0/s1
|
|||
| InChIKey |
KURQKNMKCGYWRJ-HNNXBMFYSA-N
|
|||
| CAS Number |
CAS 1202402-40-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Antagonist | [3] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Parkinson's disease | ||||
| Alcoholism | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Reactome | NGF-independant TRKA activation | |||
| Adenosine P1 receptors | ||||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Nucleotide GPCRs | |||
| Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02253745) Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May;28(5):455-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.